Galapagos NV (GLPGF)
| Previous Close | 26.20 |
| Open | 26.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 26.20 - 26.20 |
| 52 Week Range | 26.20 - 41.75 |
| Volume | |
| Avg. Volume | 1,045 |
| Market Cap | 1.727B |
| Beta (5Y Monthly) | 0.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.06 |
| Earnings Date | Aug 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Galapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)
Galapagos ( AMS:GLPG ) First Quarter 2024 Results Key Financial Results Revenue: €62.4m (down 65% from 1Q 2023). Net...
GlobeNewswireGalapagos reports first quarter 2024 financial results
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 202
- GlobeNewswire
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. The AGM approved, amongst other items: The Remuneration Report and revised Remuneration PolicyThe remuneration of the members of the Board of DirectorsThe reappointment of Dr. Elisabeth Svanberg as Independent Non-Executive Director The appointments of D
